Intravenous immune globulin prophylaxis in recipients of a marrow transplant

The Journal of Allergy and Clinical Immunology

Volumn 84, Issue 4 PART 2, 1989, Pages 632-639

  Sullivan, Keith M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS; HUMAN; HUMAN CELL; INTRAVENOUS ADMINISTRATION; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GRAFT VS HOST DISEASE; HUMAN; IMMUNIZATION, PASSIVE; INFUSIONS, INTRAVENOUS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 45349113169     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-6749(89)90202-9     Document Type: Article

References (46)

1. Allogeneic and syngeneic bone marrow transplant activity worldwide. A report from The International Bone Marrow Transplant Registry (IBMTR) [Abstract]
2. Bone-marrow transplantation
3. Bone-marrow transplantation
4. Long-term results of allogeneic bone marrow transplantation
5. Perspective: indications for marrow transplantation in chronic myelogenous leukemia
6. A review: the kinetics of immune reconstitution after human marrow transplantation
7. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment
8. Analysis of late infections, after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graftversus-host disease
9. Use of thymic grafts or thymic factors to augment immunologic recovery after bone marrow transplantation: brief report with 2 to 12 years follow-up
10. In vitro regulation of immunoglobulin synthesis after human marrow transplantation. II. Deficient T and non-T lymphocyte function within 3–4 months of allogeneic, syngeneic, or autologous marrow grafting for hematologic malignancy
11. Serum immunoglobulin levels following allogeneic marrow transplantation
12. Immunoglobulin E levels following allogeneic, autologous and syngeneic bone marrow transplantation: an indirect association between hyperproduction and acute graft-versus-host disease in allogeneic BMT
13. Prednisone and azathioprine compared to prednisone and placebo for treatment of chronic graft-versus-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation
14. Risk factors for airflow obstruction in recipients of bone marrow transplants
15. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-versus-host disease and low serum IgG
16. Deficiency of intestinal immunity with graft-vs-host disease in humans
17. Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease
18. Long lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogeneic marrow transplantation
19. The regulation of immunoglobulin synthesis after HLA-identical bone marrow transplantation. VI: Differential rates of maturation of distinct functional groups within lymphoid subpopulations in patients after human marrow grafting
20. Acute and chronic graft-versus-host disease in man
21. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants
22. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia
23. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: beneficial effect of a protective environment
24. The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four-arm randomized study
25. Chronic graft-versus-host disease: recent advances in diagnosis and treatment
26. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease
27. Functional asplenia after bone marrow transplantation: a late complication related to extensive chronic graft-versus-host disease
28. the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation
29. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
30. Infection in bone marrow transplant recipients
31. Risk factors for cytomegalovirus infection after human marrow transplantation
32. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
33. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation
34. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplant
35. Early and late interstitial pneumonia following human bone marrow transplantation
36. Transfer of allergenspecific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation
37. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation
38. Cytomegalovirus immune plasma in bone marrow transplant recipients
39. Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native unmodified cytomegalovirus globulin: randomized trial in bone marrow transplant recipients
40. Prophylaxis against cytomegalovirus infection after BMT with gamma globulins [Abstract]
41. The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients
42. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation
43. Immunoglobulin therapy in bone marrow transplantation
44. Rapid clearance of cytomegalovirus-specific IgG after repeated intravenous infusions of human immunoglobulin into allogeneic bone marrow transplant recipients
45. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study
46. Antimicrobial and immunomodulatory effects of intravenous immunoglobulin in bone marrow transplantation [Abstract]